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A B S T R A C T
Objectives: The gene encoding glucose transporter 3 (GLUT3, SLC2A3) is present in the human population at
variable copy number. An overt disease phenotype of SLC2A3 copy number variants has not been reported;
however, deletion of SLC2A3 has been previously reported to protect carriers from rheumatoid arthritis, im-
plicating GLUT3 as a therapeutic target in rheumatoid arthritis. Here we aim to perform functional analysis of
GLUT3 copy number variants in immune cells, and test the reported protective association of the GLUT3 copy
number variants for rheumatoid arthritis in a genetic replication study.
Methods: Cells from genotyped healthy controls were analyzed for SLC2A3/GLUT3 expression and glycolysis
capacity. We genotyped the SLC2A3 copy number variant in four independent cohorts of rheumatoid arthritis
and controls and one cohort of multiple sclerosis and controls.
Results: Heterozygous deletion of SLC2A3 correlates directly with expression levels of GLUT3 and influences
glycolysis rates in the human immune system. The frequency of the SLC2A3 copy number variant is not different
between rheumatoid arthritis, multiple sclerosis and control groups.
Conclusions: Despite a robust SLC2A3 gene copy number dependent phenotype, our study of large groups of
rheumatoid arthritis cases and controls provides no evidence for rheumatoid arthritis disease protection in
deletion carriers. These data emphasize the importance of well powered replication studies to confirm or refute
genetic associations, particularly for relatively rare variants.
1. Introduction
Distinct metabolic profiles characterize the main players in rheu-
matoid arthritis (RA) pathogenesis. For example, CD4+ effector T cells
preferentially utilize glycolysis upon activation and upregulate their
expression of glucose transporters GLUT1 and GLUT3, while induced
regulatory T cells favor oxidative lipid metabolism [1,2]. The gene
encoding GLUT3, SLC2A3, is copy number variable in humans [3] and
heterozygous deletion is reported to protect carriers from developing
RA [3]. A deletion or duplication of 129 kb at chromosome 12p13.31
results in variants of one or three (or more) total SLC2A3 gene copies
respectively. Heterozygous deletion at SLC2A3 is consistently found in
0.5–1% of individuals, while one or more duplications are found in
approximately 4% of normal subjects across multiple populations [3,4].
The protective association of SLC2A3 for RA implicates GLUT3 as a
potential therapeutic target in treatment or prevention of RA.
The emerging data on the metabolic changes that accompany im-
mune activation prompted us to explore the effects of the human
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SLC2A3 CNVs on the metabolism of immune cells that have been im-
plicated in RA, as well as to replicate the previous association data.
2. Results
2.1. SLC2A3 CNV genotype calling approach
Copy number variants (CNVs) can be challenging to accurately de-
fine, and accurate genotyping is best carried out by a variety of com-
plementary methods. Here we focus on qPCR and estimates from SNP
array data. To validate our genotyping methods we utilized GAP and
NYCP control cohorts, described previously, for which we obtained SNP
chip array values and DNA for typing via PCR methods [5,6]. Quanti-
tative PCR (qPCR) revealed a number of false positive and false nega-
tive CNV calls by PennCNV [21] (tableS1, tableS2). By plotting B allele
frequency (BAF) and logR ratios (LRR) we verified that visual inspec-
tion could corroborate qPCR CNV calls (Fig. 1A–C). In the GAP and
NYCP control sets, all subjects that received discrepant PennCNV and
qPCR CNV calls (or high LRR SD or NumCNV values) were inspected
visually, and all visual calls agreed with qPCR genotypes, verifying that
the mismatches were due to false negative or false positive PennCNV
calls. We introduced a third method to estimate SLC2A3 copy number
from known CNV interval positions [3]. This method compared LRR
values of SNPs inside the known CNV breakpoints, to values 350 kbps
either side of the CNV interval (Fig. 1D) and calculated fit to expected
BAF values within the CNV interval for a duplication, deletion or a
normal diploid interval (Fig. 1E). Results from this method agreed with
qPCR and visual inspection calls for all subjects in the GAP and NYCP
datasets (Fig. 1F). Due to the nature of performing large genetic studies,
it is not always possible to obtain both genomic DNA to perform qPCR,
Fig. 1. SLC2A3 CNV genotyping. Representative images of data plots used for visual calls of copy number in a deletion carrier (A), normal subject (B) and a
duplication carrier (C). Plots show BAF (top), LRR (middle) or cumulative [22] LRR (bottom) by chromosomal position. Vertical dotted lines depict the breakpoints of
the known CNV interval and the positions of the SLC2A3 and SLC2A14 genes are depicted as indicated. The new CNV specific algorithm uses P value cutoffs and an
expected BAF value fit ratio threshold to call SLC2A3 copy number. P values of t-tests comparing LRR of SNPs inside the CNV breakpoints to LRR of SNPs 350 kb
either side of the CNV interval (D) or minimum P value versus BAF value fit ratio (E). QPCR values of genomic DNA samples classified as 1, 2 or 3 copies by SNP array
methods and visual calls.
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and SNP chip array values in order to confirm CNV calls by com-
plementary methods. Our analysis here show that, in the absence of
using qPCR to validate PennCNV calls, that combining PennCNV with
visual inspection and a CNV specific calling method is sufficient for
false calls by PennCNV to be detected and corrected for.
2.2. SLC2A3 CNV frequencies in RA cases, MS cases and controls
In an attempt to replicate the previous report of an association with
RA susceptibility [3], to which our group contributed, we genotyped
the SLC2A3 CNV in four independent groups of RA cases and controls
(tableS1)[7,8]. Comparisons of CNV frequencies between cases and
controls within groups revealed no compelling evidence for either a risk
or protective association, despite the large sample sizes (Fig. 2, ta-
bleS3). The sample sizes of these cohorts (1 to 4) ensured good power to
replicate the initial protective associations reported in Swedish cases
and controls [3] at 99.99%, 91.8%, 89.1% and 67.5% respectively
(table s6). We tested for any effects of the CNVs on clinical covariates
within RA cases and did not observe any effect of SLC2A3 gene copy
number on disease severity measures (figureS1).
We further tested the subgroups within each group (which differ by
genotyping method or genotyping array) to confirm the validity of
combining the groups for association testing (tableS7). Only the Korean
control subgroups showed evidence for significant heterogeneity. We
note that the relatively small size may explain this result for the Korean
control groups. We also genotyped the SLC2A3 CNV in 450 families
with autoimmune disease from the Multiple Autoimmune Disease
Genetic Consortium (MADGC) to look for association with RA or au-
toimmune disease in general [9]. As shown in Fig. 2, we observed that
the deletion in RA patients was not less than the observed frequencies in
controls. Interestingly, within the MADGC family members affected
with multiple sclerosis (MS) we observed significant enrichment of the
deletion at 2.7%. To follow on from this suggestive deleterious asso-
ciation, we analyzed the SLC2A3 CNV in 10,667 MS cases from the
Wellcome Trust Case Control Consortium (WTCCC) [10]. The deletion
was observed at a frequency of 0.66%, a frequency not significantly
different than matched controls, or observed in any of our other control
datasets.
2.3. SLC2A3 CNV genotype correlates with expression level and glycolysis
As these genetic data were being developed, we endeavored to de-
monstrate whether GLUT3 deletions have an effect on immune meta-
bolism. GLUT3 expression is reported in monocytes and T lymphocytes
in the human immune system [11], and in activated T lymphocytes in
the murine immune system [1]. To confirm strong expression of GLUT3
protein in the human immune system we isolated and activated major
cell subsets. Despite evidence for expression of SLC2A3 transcript in
human neutrophils [12] we were unable to detect robust expression of
GLUT3 protein in resting or activated neutrophils. Consistent with the
non-glycolytic state of quiescent cells, GLUT3 protein was absent or
very weak in the absence of activating factors [13], and strongly in-
duced following activation. The strongest expression of GLUT3 protein
was observed in monocyte derived macrophages and blasting T lym-
phocytes (figureS2). We isolated T cells and monocytes from PBMC of
genotyped controls and cultured to T-blasts and macrophages to com-
pare transcript and protein expression by SLC2A3 gene copy number.
We observed a significant reduction of GLUT3 expression at both the
transcript and protein level in subjects carrying the deletion (Fig. 3A–B)
compared with subjects with 2 or 3 copies of the gene. In T-blasts we
observed an increase in SLC2A3 transcript of subjects carrying 3 copies
of the SLC2A3 gene, compared with subjects with 2 copies, however, we
were unable to detect a similar increase at the protein level. Notably,
GLUT14 protein is unlikely to be present at functional levels as ex-
pression of SLC2A14 transcript was undetectable in most samples, and
at its highest level, SLC2A14 is > 2000 fold lower than expression of
SLC2A3.
We also measured expression of the GLUT1 gene transcript
(SLC2A1) and expression of genes neighboring the CNV locus. The ex-
pression of CLEC4C and FOXJ2 is not affected by the SLC2A3 CNVs, but
Fig. 2. Genetic association of SLC2A3 CNVs in RA cases, MS cases and controls. The number, and frequency, of deletion and duplication CNVs, and total subjects
genotyped is given for each group of cases and controls. The odds ratios± 95% confidence intervals (error bars) are plotted on a log2 scale. Group details are
supplied in online supplementary table S1. P values are from chi-square test statistic.
K.R. Simpfendorfer, et al. Molecular Genetics and Metabolism Reports 19 (2019) 100470
3
reduced expression of NANOG was observed in T cells of deletion car-
riers. However, the effect is unlikely to disrupt T cell function as ex-
pression of SLC2A3 is at least 50 fold greater than the expression of
NANOG (figureS3).
To determine the effect of altered GLUT3 expression levels on me-
tabolic functions we measured the extracellular acidification rate
(ECAR) as a proxy of glycolysis of activated T-blasts and macrophages.
We observed that both cell types reached maximal glycolysis rates in
the absence of mitochondrial inhibition, and that ECAR was lower in
deletion carriers than subjects with two copies of SLC2A3 (Figs. 3C–D).
3. Discussion
Prompted by a previous study of protection from RA, we explored
the biological effects of SLC2A3 deletion on immune cell function. The
results clearly indicate that the presence of a heterozygous SLC2A3
deletion correlates with reduced glycolysis rates and a reduction of
GLUT3 expression in both T cells and macrophages of individuals
Fig. 3. Correlation of GLUT3 expression and glycolysis to SLC2A3 gene copy number. The level of SLC2A3 and SLC2A14 transcript (A) in genotyped control subject T
cells activated with anti-CD3/anti-CD28 coated beads (T-blasts 10 days) and in monocytes differentiated into macrophages with M-CSF (14 days). B) GLUT3 protein
levels in T-blasts (day 10) detected with anti-GLUT3 (EPR10508(N)) rabbit monoclonal antibody. Glycolysis measured as extracellular acidification rates (ECAR) in
genotyped control subject's LPS activated macrophages (14 days) (extracellular acidification occurs predominately from the excretion of lactic acid after its con-
version from pyruvate during glycolysis) (C) and PMA and ionomycin activated T-blasts (7 days) (D). The level of detection is indicated by the dotted line in A. In A
and B each symbol represents one unique control subject, horizontal lines indicate the mean ± SD. In C and D each line represents one unique control subject and
symbols represent the mean ± SEM for each genotype group, groups are nudged to prevent symbol overlap. Statistical significance of expression and protein data
was tested using a two-tailed Mann-Whitney U test and is denoted as *p < .05, **p < .01, ***p < .001. Statistical significance of ECAR data (P values shown) was
calculated by unpaired t-test of AUC (one-tailed). Genotyped subjects of SLC2A3 copy number 1 are circles, copy number 2 are squares and copy number 3 are
diamonds. As previously reported we noted that GLUT3 protein aggregates to form high molecular weight smears in Western blot of boiled lysate and that copy
number dependent protein levels at 54 kDa could only be observed in the absence of boiling (see online supplementary fig. S5).
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carrying this genotype. However, the protective association with RA
(OR~0.5) was not confirmed (combined OR=0.87[0.67–1.14]). We
also did not observe evidence of an association with multiple sclerosis,
despite initial encouraging results in multiplex families with auto-
immunity.
There are a number of possible explanations of why this study did
not replicate the previously reported association of protection from RA
with the SLC2A3 deletion. Foremost, we note that our current data
reveal that the number of PennCNV false calls can be significant
(tableS4). By their nature, random sampling of rare events can lead to
false differences more often than common events [14]. We analyzed 15
groups of cases and controls of European ancestry and the highest
frequency of the deletion that we observed was of 1.4% in 712 RA
cases. In comparison, the frequency of the deletion reported in Swedish
controls in the original study was 2.6%. In comparison, the frequency of
the deletion reported in RA cases was 1.17%, which is not less than the
frequency reported in their US or UK controls, or any of our control
groups of European ancestry.
Our result is consistent with two previous genome-wide CNV asso-
ciation studies that also found no association of the SLC2A3 CNV with
RA [15,16], however, we note that these studies may have been un-
derpowered to detect a statistically significant difference in frequency
of the uncommon SLC2A3 CNV.
Maintenance of SLC2A3 CNVs in the human population at fairly
constant frequencies between ethnically diverse groups (Fig. 2, tableS5)
suggests selective advantages may exist for these variants. The reduced
expression of GLUT3 associated with genetic deletion of SLC2A3 could
offer some level of protection to the host from infection with Chlamydia
bacteria [17] and blood-stage parasites that rely on GLUT3 from their
host cells for glucose metabolism [18].
In summary these results confirm that deletion of SLC2A3 correlates
directly with expression levels of GLUT3 and glycolysis rates in the
human immune system, but are not associated with protection from RA
or susceptibility to MS. Our improved method of CNV allele calling
should permit future exploration of whether SLC2A3 CNVs have an
impact on other immune phenotypes such as susceptibility to infection.
In addition, since associations of SLC2A3 with several CNS phenotypes
has been suggested [19,20], our methods should also be applied to the
emerging large GWAS datasets of these disorders.
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